Welcome to our dedicated page for vvy news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on vvy stock.
Vivoryon Therapeutics N.V. (symbol: VVY) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for age-related diseases. The company focuses primarily on combating neurodegenerative conditions such as Alzheimer's disease. The core business of Vivoryon involves the research and development of drug candidates that target specific enzymes implicated in the pathogenesis of these diseases.
One of the company's flagship projects is the development of varoglutamstat (PQ912), a first-in-class therapy aimed at inhibiting the enzyme glutaminyl cyclase (QC). This enzyme is known to play a significant role in the formation of toxic proteins associated with Alzheimer's disease. Vivoryon's approach is designed to slow down or halt disease progression by reducing the build-up of these harmful proteins.
Recent achievements include the successful completion of Phase IIb clinical trials for varoglutamstat, which demonstrated promising efficacy and safety profiles. The company is now gearing up for Phase III trials and has received positive feedback from regulatory authorities.
In addition to varoglutamstat, Vivoryon is exploring other therapeutic candidates and biomarkers that could potentially address various aspects of neurodegenerative and age-related disorders. The company's robust pipeline showcases its commitment to expanding its portfolio through both in-house research and strategic partnerships.
Financially, Vivoryon maintains a strong position with a diversified funding strategy that includes grants, partnerships, and equity financing. The company's recent financial results highlighted steady progress in R&D expenditures, reflecting its focused investment in advancing its clinical programs.
Vivoryon collaborates with leading academic institutions and industry partners to leverage cutting-edge research and technology. These partnerships are crucial for accelerating the development of its therapeutic candidates and ensuring access to the latest scientific advancements.
Overall, Vivoryon Therapeutics N.V. is at the forefront of developing new treatments for age-related diseases, with a particular focus on neurodegeneration. Its innovative approach, strong financial health, and strategic partnerships position the company as a significant player in the biopharmaceutical industry.
Vivoryon Therapeutics N.V. announces participation in two key investor conferences:
- Van Lanschot Kempen Life Sciences Conference on April 25-26, 2023, featuring one-on-one meetings in Amsterdam.
- Bio€quity Europe on May 14-16, 2023, with a presentation scheduled for May 16, 2023, at 10:44 am IST in Dublin.
As a clinical-stage biotechnology company, Vivoryon focuses on developing small molecule medicines aimed at modulating pathologically altered proteins, including its lead program, varoglutamstat, which targets Alzheimer’s disease in Phase 2 clinical development. The company is committed to advancing treatments for severe diseases, utilizing extensive expertise in protein modifications.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) reported its full-year 2022 financial results, highlighting advancements in clinical trials for varoglutamstat, a potential treatment for Alzheimer’s disease. The VIVIAD and VIVA-MIND studies progressed significantly, with final data from VIVIAD expected in Q1 2024 and a clinical update on VIVA-MIND anticipated in 2H 2023. The company bolstered its financial position with two successful private placements totaling EUR 36 million, with an option for up to an additional EUR 15 million. Despite a net loss of EUR 28.2 million in 2022, an increase from EUR 12.7 million in 2021, the cash balance at year-end stood at EUR 26.6 million, supporting operations through at least December 2023. Management is optimistic about ongoing trials and the potential for future partnerships.
Vivoryon Therapeutics N.V. will report its full year 2022 financial results and operational progress on April 19, 2023. The conference call is scheduled for 03:00 pm CEST / 09:00 am EDT and will be available via phone and webcast. The report will be accessible on their website. Vivoryon is dedicated to developing small molecule medicines aimed at modulating altered proteins in various diseases, including a lead program in Phase 2 clinical trials for Alzheimer’s disease. The company is also advancing a solid pipeline of molecules targeting other conditions such as cancer and fibrosis.
Vivoryon Therapeutics N.V. recently provided an update on its clinical development of varoglutamstat, targeting Alzheimer's disease (AD). The VIVIAD Phase 2b study in Europe is set for final data in Q1 2024, demonstrating positive safety results in over 100 patients with no on-target toxicity or ARIA signs. In the U.S., the VIVA-MIND Phase 2 study is progressing with 18 sites actively enrolling patients. Both studies indicate low discontinuation rates and effective recruitment strategies. Varoglutamstat's design aims to address key AD challenges, enhancing patient treatment adherence and targeting neurotoxic pathways.
Vivoryon Therapeutics N.V. announced that CEO Dr. Ulrich Dauer will present at significant investor conferences in March 2023. The events include the BioCapital Europe 2023 on March 9, the Barclays Global Healthcare Conference on March 16, and the German Biotechnology Days on March 29. A webcast of these presentations will be accessible on their website.
FAQ
What is Vivoryon Therapeutics N.V.?
What is the main focus of Vivoryon's research?
What is varoglutamstat (PQ912)?
What recent achievements has Vivoryon made?
How is Vivoryon funded?
Who are Vivoryon's partners?
What other therapeutic candidates is Vivoryon developing?
How does Vivoryon contribute to Alzheimer's research?
What are the future plans for Vivoryon?
How can I get more information about Vivoryon's latest news?
